From: Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada
Study (year) | Description of cost | Cost year | Currency | Mean cost |
---|---|---|---|---|
France | ||||
Fourcade et al. (2010) [17] | Total direct cost of treatment in 12 months after diagnosis, excluding follow up and adverse event costs, for all diagnosed patients | 2006 | EUR | 5851 |
Molinier et al. (2011) [44] | Mean total cost (all prostate cancer) | 2008 | EUR | 12,731 |
Mean total cost localized | 2008 | EUR | 12,259 | |
Mean total cost regional | 2008 | EUR | 16,608 | |
Mean total cost metastatic | 2008 | EUR | 9994 | |
Germany | ||||
Fourcade et al. (2010) [17] | Total direct cost of treatment in 12 months after diagnosis, excluding follow up and AE costs, for all diagnosed patients | 2006 | EUR | 3698 |
UK | ||||
Hall et al. (2015) [45] | Cumulative hospital-based costs of care over 15 months following initial diagnosis in patients treated with curative intent | 2011/12 | GBP | 3722 (95% CI, 3263–4208) |
Fourcade et al. (2010) [17] | Total direct cost of treatment in 12 months after diagnosis, excluding follow up and AE costs, for all diagnosed patients | 2006 | EUR | 3682 |
Marti et al. (2016) [46] | Total societal (and component costs) in prostate cancer survivors treated with curative intent over 12–15 months post-diagnosis period | |||
Total societal cost (per month) | 2012 | GBP | 117.9 (95% CI: 68.9–167.0) | |
NHS costs (per month) | 2012 | GBP | 92.1 (49.3–134.9) | |
Patient OOP costs (per month) | 2012 | GBP | 7.2 (2.3–12.0) | |
Informal care costs (per month) | 2012 | GBP | 16.4 (−5.5–38.3) | |
Canada | ||||
De Oliveira et al. (2013) [47] | Total healthcare costs in 12 months after diagnosis in patients aged ≥45 years | 2009a | CAD | 15,170 |
Krahn et al. (2010) [48] | Direct medical costs for men diagnosed 1995–2002 according to phase | 2004 | CAD | |
Phase Ib (costs incurred in 6 months prior to prostate cancer diagnosis) | 2004 | CAD | 1904 | |
Phase IIb (costs incurred in first 12 months after prostate cancer diagnosis) | 2004 | CAD | 12,005 | |
Phase IIIb (“continued care” phase, costs per 100 days) | 2004 | CAD | 1495 | |
Phase IVb (pre-terminal care in 18 to 6 months before death) | 2004 | CAD | 20,543 | |
Phase Vb (terminal care, 6 months before death) | 2004 | CAD | 28,834 | |
De Oliveira et al. (2014) [49] | Patient time costs per year (all) | 2006 | CAD | 838 (442–1233) |
Out of pocket costs per year (all) | 2006 | CAD | 200 (109–290) | |
Krahn et al. (2014) [50] | Early health states: non-treated, non-metastatica | 2008 | CAD | 3440 |
Early health states: radiation therapya | 2008 | CAD | 2160 | |
Early health states: radical prostatectomya | 2008 | CAD | 4676 | |
Early health states: hormone therapya | 2008 | CAD | 3357 | |
Middle health states: post-radiation therapya | 2008 | CAD | 1556 | |
Middle health states: post-radical prostatectomya | 2008 | CAD | 732 | |
Middle health states: recurrence/progressiona | 2008 | CAD | 1919 | |
Late health states: hormone therapy refractorya | 2008 | CAD | 4503 | |
Late health states: metastatica | 2008 | CAD | 4062 | |
Late health states: metastatic refractorya | 2008 | CAD | 6398 | |
Late health states: finala | 2008 | CAD | 13,739 | |
Sanyal et al. (2016) [51] | Total overall cost (overall cohort) at: | |||
5 years | 2014 | CAD | 18,503 (17,851–19,185) | |
10 years | 2014 | CAD | 28,032 (26,129–29,973) | |
15 years | 2014 | CAD | 39,143 (36,606–41,821) | |
Dragomir et al. (2014) [52] | Active surveillance; cost first 5 years | 2012 | CAD | 6200 (6083 to 6317) |
Immediate treatment; cost first 5 years | 2012 | CAD | 13,735 (13,615 to 13,855) |